As the popularity of stock picking rises, so do the prospects of long/short equity hedge funds that have helped to drive assets to a struggling hedge fund industry.
A number of launches in the second quarter centered on TMT and biotech sector specialist strategies including firms such as OrbiMed’s New Horizons Fund; biotech fund M28 Capital; Dilation Capital, founded by Lone Pine alum Brian Eizenstat; and the EFF offering from UBS O’Connor.
According to data firm PivotalPath, the majority of hedge fund launches have been either equity diversified or equity sector managers . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. We offer pay-as-you-go monthly subscriptions and discounted annual subscriptions with additional benefits: access to Alternatives Watch Research articles and our Annual Investor Compendium.
